CNTA (Centessa Pharmaceuticals) Moat Score: 5/10 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNTA Centessa Pharmaceuticals PLC CNTA
12 GF Score
Price $40.50
! 4 Warning Signs
View Full Analysis

What is Centessa Pharmaceuticals Moat Score?

Centessa Pharmaceuticals CNTA 12 Moat Score is 5 as of Jul. 18, 2026. GuruFocus rates CNTA with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 1,396 Biotechnology companies, Centessa Pharmaceuticals ranks better than 96.7% on this metric.

Centessa Pharmaceuticals has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Centessa Pharmaceuticals has Narrow Moat: Centessa Pharmaceuticals PLC has a solid narrow moat due to its innovative drug development pipeline and valuable intellectual property. However, it faces significant competition and regulatory hurdles in the pharmaceutical industry, limiting its moat to a narrow category.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Centessa Pharmaceuticals might have Narrow Moat - Solid narrow moat.

Centessa Pharmaceuticals  (NAS:CNTA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Centessa Pharmaceuticals Moat Score Related Terms

CNTA vs CGON, LGND, COGT: Moat Score Comparison

For the Biotechnology subindustry, Centessa Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Centessa Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Centessa Pharmaceuticals's Moat Score falls into.


CNTA
12GF Score
Centessa Pharmaceuticals PLC CNTA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Centessa Pharmaceuticals (CNTA) has a Moat Score of 5 as of Jul. 18, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Centessa Pharmaceuticals ranks #46 out of 1396 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Centessa Pharmaceuticals' Moat Score too high?
Centessa Pharmaceuticals' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Centessa Pharmaceuticals' value of 5 is 150% above this industry median. Based on the distribution chart, Centessa Pharmaceuticals ranks #46 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Centessa Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Centessa Pharmaceuticals' Moat Score compare to CGON and LGND?
According to the Biotechnology industry distribution chart, Centessa Pharmaceuticals ranks #46 out of 1396 companies for Moat Score. This places Centessa Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Centessa Pharmaceuticals' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Centessa Pharmaceuticals's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Centessa Pharmaceuticals's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centessa Pharmaceuticals stock overvalued right now?
Centessa Pharmaceuticals (CNTA) has a current Moat Score of 5. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Centessa Pharmaceuticals' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Centessa Pharmaceuticals (CNTA), the current Moat Score is 5 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Centessa Pharmaceuticals Business Description

Other Exchanges 0ACX:UK260:Germany
Address 1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
12GF Score

Get the complete analysis for CNTA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$40.50
Price